Target Information

Target General Information

Top

Target ID

T67952 (Former ID: TTDR00174)

Target Name

Potassium channel unspecific (KC)

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 9 Target-related Diseases

Acute diabete complication [ICD-11: 5A2Y]

Angina pectoris [ICD-11: BA40]

Cardiac arrhythmia [ICD-11: BC9Z]

Essential hypertension [ICD-11: BA00]

Hypertension [ICD-11: BA00-BA04]

Lambert-Eaton syndrome [ICD-11: 8C62]

Multiple sclerosis [ICD-11: 8A40]

Supraventricular tachyarrhythmia [ICD-11: BC81]

Ventricular tachyarrhythmia [ICD-11: BC71]

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 9 Approved Drugs

Amifampridine

Drug Info

Approved

LambertEaton myasthenic syndrome

[4]

Amiodarone

Drug Info

Approved

Tachyarrhythmias

[5], [6]

Dalfampridine

Drug Info

Approved

Multiple sclerosis

[7]

Diazoxide

Drug Info

Approved

Hypertension

[8], [9]

Dofetilide

Drug Info

Approved

Sinus rhythm disorder

[6], [10]

Dronedarone

Drug Info

Approved

Angina pectoris

[11], [12]

Ibutilide

Drug Info

Approved

Atrial fibrillation

[6], [13]

Nateglinide

Drug Info

Approved

Diabetic complication

[14], [15]

Pinacidil

Drug Info

Approved

High blood pressure

[16], [17]

Clinical Trial Drug(s)

[+] 16 Clinical Trial Drugs

Andolast

Drug Info

Phase 3

Rhinitis

[18]

Azimilide

Drug Info

Phase 3

Atrial fibrillation

[6], [19]

ATI-2042

Drug Info

Phase 2

Atrial fibrillation

[20]

AZD-7009

Drug Info

Phase 2

Atrial fibrillation

[21]

Bimakalim

Drug Info

Phase 2

Angina pectoris

[22]

HBI-3000

Drug Info

Phase 2

Heart arrhythmia

[23]

K-201

Drug Info

Phase 2

Atopic dermatitis

[24]

MSH-1001

Drug Info

Phase 2

Ocular hypertension

[25]

RP-49356

Drug Info

Phase 2

Hypertension

[26]

YM-934

Drug Info

Phase 2

Angina pectoris

[27]

AVE0118

Drug Info

Phase 1

Obstructive sleep apnea

[28]

CLP-1004

Drug Info

Phase 1

Hypertension

[29]

Iptakalim

Drug Info

Phase 1

Hypertension

[30]

Nibentan

Drug Info

Phase 1

Cardiac arrhythmias

[31]

NS-8

Drug Info

Phase 1

Urinary incontinence

[32]

UK-66914

Drug Info

Phase 1

Cardiac arrhythmias

[33]

Discontinued Drug(s)

[+] 38 Discontinued Drugs

Levcromakalim

Drug Info

Discontinued in Preregistration

Chronic obstructive pulmonary disease

[34]

Acecainide

Drug Info

Discontinued in Phase 3

Solid tumour/cancer

[36]

Alinidine

Drug Info

Discontinued in Phase 3

Angina pectoris

[37]

BMS-204352

Drug Info

Discontinued in Phase 3

Nerve injury

[38], [39]

BMS-180448

Drug Info

Discontinued in Phase 2

Angina pectoris

[42]

BRL-32872A

Drug Info

Discontinued in Phase 2

Cardiac arrhythmias

[43]

BRL-55834

Drug Info

Discontinued in Phase 2

Chronic obstructive pulmonary disease

[44]

E-4031

Drug Info

Discontinued in Phase 2

Cardiac arrhythmias

[45], [46]

JTV-506

Drug Info

Discontinued in Phase 2

Angina pectoris

[47]

KCO-912

Drug Info

Discontinued in Phase 2

Chronic obstructive pulmonary disease

[48]

KW-7158

Drug Info

Discontinued in Phase 2

Urinary incontinence

[49]

P-1075

Drug Info

Discontinued in Phase 2

Hypertension

[50]

Risotilide

Drug Info

Discontinued in Phase 2

Heart arrhythmia

[51]

Y-27152

Drug Info

Discontinued in Phase 2

Angina pectoris

[52]

ZD-0947

Drug Info

Discontinued in Phase 2

Overactive bladder

[53]

Emakalim

Drug Info

Discontinued in Phase 1

Angina pectoris

[56]

NTC-801

Drug Info

Discontinued in Phase 1

Atrial flutter

[57]

Rilmakalim

Drug Info

Discontinued in Phase 1

Chronic obstructive pulmonary disease

[58]

Ro-31-6930

Drug Info

Discontinued in Phase 1

Hypertension

[59]

SR-47063

Drug Info

Discontinued in Phase 1

Cardiac arrhythmias

[60]

Symakalim

Drug Info

Discontinued in Phase 1

Hypertension

[61]

AL-0671

Drug Info

Terminated

Arteriosclerosis

[65]

AWD-23-111

Drug Info

Terminated

Heart arrhythmia

[66]

E-4080

Drug Info

Terminated

Angina pectoris

[67]

ICI-181037

Drug Info

Terminated

Heart arrhythmia

[68]

Ki-1769

Drug Info

Terminated

Hypertension

[69]

NS-004

Drug Info

Terminated

Hypertension

[70], [71]

NS-1608

Drug Info

Terminated

Cerebrovascular ischaemia

[72]

Org-20781

Drug Info

Terminated

Heart arrhythmia

[73]

S-1389

Drug Info

Terminated

Heart arrhythmia

[74]

SB-237376

Drug Info

Terminated

Arrhythmia

[75]

TCV-295

Drug Info

Terminated

Hypertension

[76]

TERIKALANT

Drug Info

Terminated

Cardiac arrhythmias

[77]

UR-8225

Drug Info

Terminated

Asthma

[78]

UR-8308

Drug Info

Terminated

Asthma

[79]

UR-8328

Drug Info

Terminated

Asthma

[80]

WAY-123223

Drug Info

Terminated

Heart arrhythmia

[81]

YM-099

Drug Info

Terminated

Hypertension

[82]

Mode of Action

[+] 6 Modes of Action

Blocker

[+] 7 Blocker drugs

Amifampridine

Drug Info

[4]

HBI-3000

Drug Info

[88]

YM-934

Drug Info

[93]

Nibentan

Drug Info

[96], [97]

UK-66914

Drug Info

[99]

Alinidine

Drug Info

[102]

Trecetilide fumarate

Drug Info

[96], [141]

Modulator

[+] 22 Modulator drugs

Amiodarone

Drug Info

[1]

Dalfampridine

Drug Info

[7]

Diazoxide

Drug Info

[1]

Dofetilide

Drug Info

[1]

Ibutilide

Drug Info

[1]

Nateglinide

Drug Info

[1]

Pinacidil

Drug Info

[1]

Azimilide

Drug Info

[85]

AZD-7009

Drug Info

[87]

K-201

Drug Info

[89], [90]

AVE0118

Drug Info

[94]

Levcromakalim

Drug Info

[100]

BMS-204352

Drug Info

[103]

BRL-32872A

Drug Info

[105], [106]

E-4031

Drug Info

[108]

SB-237376

Drug Info

[75]

TERIKALANT

Drug Info

[131]

HMR1883

Drug Info

[137]

L 691121

Drug Info

[138]

MJ-451

Drug Info

[139]

RP-66471

Drug Info

[140]

Y-26763

Drug Info

[142], [143]

Inhibitor

[+] 2 Inhibitor drugs

Dronedarone

Drug Info

[83]

NTC-801

Drug Info

[117]

Opener

[+] 30 Opener drugs

Andolast

Drug Info

[84]

MSH-1001

Drug Info

[91]

RP-49356

Drug Info

[92]

Iptakalim

Drug Info

[30], [96]

Acecainide

Drug Info

[101]

BRL-55834

Drug Info

[107]

JTV-506

Drug Info

[109]

P-1075

Drug Info

[112]

Risotilide

Drug Info

[113]

Y-27152

Drug Info

[114]

ZD-0947

Drug Info

[115]

Emakalim

Drug Info

[116]

Rilmakalim

Drug Info

[118]

Ro-31-6930

Drug Info

[119]

SR-47063

Drug Info

[120]

AL-0671

Drug Info

[122]

AWD-23-111

Drug Info

[123]

E-4080

Drug Info

[124]

ICI-181037

Drug Info

[125]

Ki-1769

Drug Info

[126]

NS-004

Drug Info

[71]

NS-1608

Drug Info

[127]

Org-20781

Drug Info

[128]

S-1389

Drug Info

[129]

TCV-295

Drug Info

[96], [130]

UR-8225

Drug Info

[132]

UR-8308

Drug Info

[133]

UR-8328

Drug Info

[134]

WAY-123223

Drug Info

[135]

YM-099

Drug Info

[136]

Agonist

[+] 7 Agonist drugs

ATI-2042

Drug Info

[86]

Bimakalim

Drug Info

[22]

NS-8

Drug Info

[98]

BMS-180448

Drug Info

[104]

KCO-912

Drug Info

[110]

KW-7158

Drug Info

[111]

Symakalim

Drug Info

[121]

Binder

[+] 1 Binder drugs

CLP-1004

Drug Info

[95]

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target-Related Models and Studies

Top

Target QSAR Model

References

Top

REF 1

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.

REF 2

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4254).

REF 3

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 071344.

REF 4

2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.

REF 5

REF 6

New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.

REF 7

Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.

REF 8

REF 9

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016996.

REF 10

REF 11

REF 12

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 13

REF 14

REF 15

Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.

REF 16

REF 17

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019456.

REF 18

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002324)

REF 19

REF 20

ClinicalTrials.gov (NCT00389792) Efficacy and Safety Study of an Antiarrhythmic Drug to Treat Atrial Fibrillation in Patients With Pacemakers. U.S. National Institutes of Health.

REF 21

ClinicalTrials.gov (NCT00255281) Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation. U.S. National Institutes of Health.

REF 22

Lack of anti-ischemic efficacy of the potassium channel opener bimakalim in patients with stable angina pectoris. Cardiovasc Drugs Ther. 2004 Jan;18(1):37-46.

REF 23

ClinicalTrials.gov (NCT01235156) Efficacy and Safety of Sulcardine Sulfate Tablets in Patients With Premature Ventricular Contractions. U.S. National Institutes of Health.

REF 24

ClinicalTrials.gov (NCT01067833) Phase 2 Study of Oral K201 for Prevention of AF Recurrence. U.S. National Institutes of Health.

REF 25

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023795)

REF 26

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000232)

REF 27

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001721)

REF 28

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019047)

REF 29

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783)

REF 30

Iptakalim: A novel multi-utility potassium channel opener. J Pharmacol Pharmacother. 2012 Jan;3(1):12-4.

REF 31

Electrophysiologic effects of nibentan (HE-11) on canine cardiac tissue. J Pharmacol Exp Ther. 1997 Mar;280(3):1137-46.

REF 32

Clinical pipeline report, company report or official report of Nippon Shinyaku Co Ltd.

REF 33

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000131)

REF 34

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000036)

REF 35

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001219)

REF 36

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000315)

REF 37

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000286)

REF 38

REF 39

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010536)

REF 40

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001764)

REF 41

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006442)

REF 42

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004365)

REF 43

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000403)

REF 44

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001581)

REF 45

REF 46

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000439)

REF 47

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006044)

REF 48

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017535)

REF 49

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013319)

REF 50

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001364)

REF 51

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002381)

REF 52

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001561)

REF 53

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009535)

REF 54

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005207)

REF 55

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001697)

REF 56

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001761)

REF 57

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023917)

REF 58

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001252)

REF 59

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000054)

REF 60

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002328)

REF 61

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003464)

REF 62

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003444)

REF 63

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006187)

REF 64

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002834)

REF 65

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005136)

REF 66

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005585)

REF 67

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001760)

REF 68

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001161)

REF 69

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002625)

REF 70

REF 71

Effects of K+ channel inhibitors and antagonists on NS-004 evoked relaxations in guinea-pig isolated trachea. Fundam Clin Pharmacol. 1997;11(1):78-82.

REF 72

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006351)

REF 73

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003350)

REF 74

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000214)

REF 75

Electrophysiologic effects of SB-237376: a new antiarrhythmic compound with dual potassium and calcium channel blocking action. J Cardiovasc Pharmacol. 2003 Mar;41(3):414-21.

REF 76

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002578)

REF 77

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001820)

REF 78

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002580)

REF 79

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005294)

REF 80

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005293)

REF 81

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001818)

REF 82

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002582)

REF 83

Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.

REF 84

BK channel modulators: a comprehensive overview. Curr Med Chem. 2008;15(11):1126-46.

REF 85

Azimilide. Drugs. 2000 Feb;59(2):271-7; discussion 278-9.

REF 86

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 87

Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. J Electrocardiol. 2014 May-Jun;47(3):316-23.

REF 88

Electrophysiological properties of HBI-3000: a new antiarrhythmic agent with multiple-channel blocking properties in human ventricular myocytes. J Cardiovasc Pharmacol. 2011 Jan;57(1):79-85.

REF 89

Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy

REF 90

JTV519 (K201) reduces sarcoplasmic reticulum Ca leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol.2012 Oct;167(3):493-504.

REF 91

KR-31378, a potassium-channel opener, induces the protection of retinal ganglion cells in rat retinal ischemic models. J Pharmacol Sci. 2009 Apr;109(4):511-7.

REF 92

Effects of pinacidil, RP 49356 and nicorandil on ATP-sensitive potassium channels in insulin-secreting cells. Br J Pharmacol. 1990 Mar;99(3):487-92.

REF 93

Potassium channel opener, YM 934, inhibits neurogenic plasma leakage in guinea pig airways. Am J Respir Crit Care Med. 1994 Nov;150(5 Pt 1):1379-83.

REF 94

Neurogenic contraction induced by the antiarrhythmic compound, AVE 0118, in rat small mesenteric arteries.Basic Clin Pharmacol Toxicol.2014 Oct;115(4):315-20.

REF 95

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036783)

REF 96

Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1128-36.

REF 97

Nibentan -- a drug for pharmacological cardioversion of persistent atrial fibrillation. Kardiologiia. 2005;45(3):19-23.

REF 98

Stimulation of large-conductance calcium-activated potassium channels inhibits neurogenic contraction of human bladder from patients with urinary symptoms and reverses acetic acid-induced bladder hyperactivity in rats. Eur J Pharmacol. 2014 Jul 15;735:68-76.

REF 99

Electrophysiologic properties of UK-66,914, a novel class III antiarrhythmic agent. J Cardiovasc Pharmacol. 1991 Mar;17(3):376-85.

REF 100

The potassium channel opener levcromakalim causes expansive remodelling of experimental vein grafts. J Vasc Surg. 2006 Jul;44(1):159-65.

REF 101

Acecainide (N-acetylprocainamide). A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cardiac arrhythmias. Drugs. 1990 May;39(5):720-40.

REF 102

Decrease in bradycardic effect of AQ-A 39 and alinidine in guinea-pig sinoatrial node depolarized by high external K+-concentration. Naunyn Schmiedebergs Arch Pharmacol. 1984 Dec;328(2):210-3.

REF 103

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

REF 104

The novel cardioprotective agent BMS-180448 activates a potassium conductance in cardiac and vascular smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 1996 Oct;354(4):444-51.

REF 105

Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile... J Pharmacol Exp Ther. 1996 Feb;276(2):637-46.

REF 106

The antiarrhythmic drug BRL-32872.Cardiovasc Drug Rev.2002 Summer;20(2):111-20.

REF 107

Comparison of the airways relaxant and hypotensive potencies of the potassium channel activators BRL 55834 and levcromakalim (BRL 38227) in vivo in guinea-pigs and rats. Br J Pharmacol. 1993 Aug;109(4):1133-9.

REF 108

Comparison of the IKr blockers moxifloxacin, dofetilide and E-4031 in five screening models of pro-arrhythmia reveals lack of specificity of isolated cardiomyocytes.Br J Pharmacol.2012 Jan;165(2):467-78.

REF 109

Effects of the new potassium channel opener JTV-506 on coronary vessels in vitro and in vivo. Arzneimittelforschung. 1999 Mar;49(3):199-206.

REF 110

KCO912: a potent and selective opener of ATP-dependent potassium (K(ATP)) channels which suppresses airways hyperreactivity at doses devoid of card... Naunyn Schmiedebergs Arch Pharmacol. 2002 Mar;365(3):220-30.

REF 111

KW-7158 [(2S)-(+)-3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide] enhances A-type K+... J Pharmacol Exp Ther. 2004 Jul;310(1):159-68.

REF 112

The effects of potassium channel opener P1075 on the human saphenous vein and human internal mammary artery. J Cardiovasc Pharmacol. 2011 Jun;57(6):648-55.

REF 113

Electrophysiological effects of left ventricular hypertrophy. Effect of calcium and potassium channel blockade. Circulation. 1991 Jun;83(6):2067-75.

REF 114

Pharmacokinetics and safety of a novel, long-acting, prodrug-type potassium channel opener, Y-27152, in healthy volunteers. J Clin Pharmacol. 1996 May;36(5):439-51.

REF 115

Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol. 2002 Aug;168(2):837-42.

REF 116

Therapeutic potential of potassium channel activators in coronary heart disease. Eur Heart J. 1994 Aug;15 Suppl C:82-8.

REF 117

Effects of the selective KACh channel blocker NTC-801 on atrial fibrillation in a canine model of atrial tachypacing: comparison with class Ic and III drugs. J Cardiovasc Pharmacol. 2014 May;63(5):421-7.

REF 118

Hypotonic stress increases efficacy of rilmakalim, but not pinacidil, to activate ATP-sensitive K(+) current in guinea pig ventricular myocytes. J Pharmacol Sci. 2004 Jun;95(2):189-95.

REF 119

Evaluation of the bronchodilator properties of Ro 31-6930, a novel potassium channel opener, in the guinea-pig. Br J Pharmacol. 1990 Jun;100(2):289-94.

REF 120

Vasorelaxant effects of the potassium channel opener SR 47063 on the isolated human saphenous vein and rat aorta. Braz J Med Biol Res. 2000 Aug;33(8):961-6.

REF 121

Synthesis and antihypertensive activity of 4-(diazabicyclo[4.1.0]-heptenyloxy)benzopyran derivatives and their analogues. Chem Pharm Bull (Tokyo). 1998 Apr;46(4):602-9.

REF 122

A possible mechanism of action of a new potassium channel opener, AL0671, on lipid metabolism in obese Zucker rats. J Pharmacol Exp Ther. 1994 Dec;271(3):1666-71.

REF 123

The new antiarrhythmic substance AWD 23-111 inhibits the delayed rectifier potassium current (IK) in guinea pig ventricular myocytes. Pharmazie. 1999 Jan;54(1):61-8.

REF 124

Ionic currents involved in vasodilating actions of E4080, a newly synthesized bradycardia-inducing agent, in dispersed smooth muscle cells of the rabbit portal vein. J Pharmacol Exp Ther. 1991 Dec;259(3):1396-403.

REF 125

ICI 181,037: a novel eukalemic diuretic with antiarrhythmic activity. Jpn J Pharmacol. 1991 Nov;57(3):263-77.

REF 126

Vasorelaxant action of Ki1769, a new pyridinecarboximidamide, in isolated porcine coronary artery. Eur J Pharmacol. 1993 Sep 14;241(2-3):177-81.

REF 127

Modulation of the Ca(2+)-dependent K+ channel, hslo, by the substituted diphenylurea NS 1608, paxilline and internal Ca2+. Neuropharmacology. 1996;35(7):903-14.

REF 128

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003350)

REF 129

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000214)

REF 130

Antihypertensive and cardiovascular effects of a new potassium channel opener, TCV-295, in rats and dogs. J Cardiovasc Pharmacol. 1994 Dec;24(6):929-36.

REF 131

Terikalant, an inward-rectifier potassium channel blocker, does not abolish the cardioprotection induced by ischemic preconditioning in the rat. J Mol Cell Cardiol. 1998 Sep;30(9):1817-25.

REF 132

Effects of the novel potassium channel opener, UR-8225, on contractile responses in rat isolated smooth muscle. Br J Pharmacol. 1993 Nov;110(3):1165-71.

REF 133

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005294)

REF 134

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005293)

REF 135

Synthesis and selective class III antiarrhythmic activity of novel N-heteroaralkyl-substituted 1-(aryloxy)-2-propanolamine and related propylamine derivatives. J Med Chem. 1991 Nov;34(11):3212-28.

REF 136

Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta. Arch Int Pharmacodyn Ther. 1994 May-Jun;327(3):330-43.

REF 137

Clamikalant (Aventis). IDrugs. 2000 Nov;3(11):1353-7.

REF 138

Embryotoxic effects of L-691,121, a class III antiarrhythmic agent, in rats. Arch Toxicol. 1994;69(1):65-71.

REF 139

Pharmacological characteristics of MJ-451, a new benzopyran- derived ATP-sensitive potassium channel opener, in guinea pig isolated trachea. Pharmacology. 1998 Dec;57(6):314-22.

REF 140

Potassium channel opener, RP 66471, induces membrane depolarization of rat liver mitochondria. Biochem Biophys Res Commun. 1995 Feb 6;207(1):126-32.

REF 141

IKr channel blockers: novel antiarrhythmic agents. Curr Med Chem Cardiovasc Hematol Agents. 2003 Oct;1(3):203-23.

REF 142

Y-26763: ATP-sensitive K+ channel activation and the inhibition of insulin release from human pancreatic beta-cells. Eur J Pharmacol. 2004 Feb 20;486(2):133-9.

REF 143

Effects of a newly synthesized K+ channel opener, Y-26763, on noradrenaline-induced Ca2+ mobilization in smooth muscle of the rabbit mesenteric art... Br J Pharmacol. 1994 Jan;111(1):165-72.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU